We attempted to evaluate the tolerability and efficacy of the antiepileptic drug oxcarbazepine
in benzodiazepine detoxification, by observing several cases. Detoxification followed
a predefined dosage scheme. All patients detoxified with oxcarbazepine completed the
withdrawal successfully, without withdrawal symptoms. The administration of oxcarbazepine
according to the scheme proved to be tolerable. The dosage was sufficient. Though
uncontrolled case observations must be interpreted with caution, oxcarbazepine appears
to be a promising drug in inpatient benzodiazepine withdrawal. It should be examined
in further randomized placebo-controlled studies including long-term follow-ups.
References
- 1
Croissant B, Scherle T, Diehl A, Heinz A, Mann K.
Oxcarbazepine in Alcohol Relapse Prevention - A Case Series.
Pharmacopsychiatry.
2004;
37
306-307
- 2
Dietrich D E, Kropp S, Emrich H M.
Oxcarbazepine in affective and schizoaffective disorders.
Pharmacopsychiatry.
2001;
34
242-250
- 3
Ghaemi S N, Berv D A, Klugman J, Rosenquist K J, Hsu D J.
Oxcarbazepine treatment of bipolar disorder.
J Clin Psychiatry.
2003;
64
943-945
- 4
Glauser T A.
Oxcarbazepine in the treatment of epilepsy.
Pharmacotherapy.
2001;
21
904-919
- 5
Rickels K, Schweizer E, Garcia Espana F, Case G, DeMartinis N, Greenblatt D.
Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy:
effects on withdrawal symptoms and taper outcome.
Psychopharmacology.
1999;
141
1-5
- 6
Sullivan J T, Sykora K, Schneiderman J, Naranjo C A, Sellers E M (1989).
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment
for alcohol scale (CIWA-Ar).
Br J Addict.
1989;
84
1353-1357
Prof. Dr. Karl Mann, MD
Department of Addictive Behavior and Addiction Medicine
Central Institute of Mental Health
University of Heidelberg J 5
68159 Mannheim
Germany
Telefon: +49 621 1703 3501
Fax: +49 621 1703 3505
eMail: sucht@zi-mannheim.de